Completion of Dosing in Phase 3 Trial
COMPASS Pathways announced the completion of dosing for all participants in Part A of their pivotal Phase III trial for treating resistant depression (TRD), marking an important milestone.
Strong Financial Position
The company reported cash and cash equivalents of $260 million at the end of March, up from $165 million at the end of 2024, expected to fund operations through Phase 3 trial COMP006 data readout in 2026.
Strategic Collaboration with HealthPort
COMPASS Pathways announced a strategic collaboration with HealthPort, a community health center focused on equitable access to mental health treatments, highlighting the company’s focus on underserved populations.
Positive Long-term Data from Phase 2b Trial
52-week follow-up data from the Phase 2b trial showed that a single 25 mg dose of COMP360 offered long-term benefits, with an average time to depressive event of over 12 weeks.